With standout facilities and strong industry links, the School prepares students for careers in health and medical science.
Doctorate in Science University Lausanne Switzerland
Master in Science Federal School Zurich (ETHZ)
Excludes commercial-in-confidence projects.
Development of an anti-cancer mitotic inhibitor MKI-77, Cancer Council SA - Beat Cancer, 01/07/2012 - 31/08/2013
Open access indicates that an output is open access.
DeWild, M, Th Muller, S, Tschumi, R, Schumacher, R & Albrecht, H 2012, 'Production and in-vitro characterization of micro-structured implant surfaces', in PJ Bartolo, Innovative Developments in Virtual and Physical Prototyping, CRC Press, UK, pp. 111-114.
Tadesse, S, Yu, M, Mekonnen, LB, Lam, F, Islam, S, Tomusange, K, Rahaman, MH, Noll, B, Basnet, SK, Teo, T, Albrecht, H, Milne, R & Wang, S 2017, 'Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation', Journal of medicinal chemistry, vol. 60, no. 5, pp. 1892-1915.
Li, P, Diab, S, Yu, M, Adams, J, Islam, S, Basnet, SK, Albrecht, H, Milne, RW & Wang, S 2016, 'Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells', Oncotarget, vol.7, no.35, pp.1-15.
Open access 1
Rahaman, MH, Kumarasiri, M, Mekonnen, LB, Yu, M, Diab, S, Albrecht, H, Milne, RW & Wang, S 2016, 'Targeting CDK9: a promising therapeutic opportunity in prostate cancer', Endocrine-related cancer, vol. 23, no. 12, pp. T211-T226.
2 1 2
Zhang, W, Garg, S, Eldi, P, Zhou, FH-h, Johnson, IR, Brooks, DA, Lam, F, Rychkov, G, Hayball, JD & Albrecht, H 2016, 'Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide', International journal of pharmaceutics, vol. 513, pp.270-279.
Basnet, SK, Diab, S, Schmid, R, Yu, M, Yang, Y, Gillam, TA, Teo, T, Li, P, Peat, T, Albrecht, H & Wang, S 2015, 'Identification of a highly conserved allosteric binding site on Mnk1 and Mnk2', Molecular Pharmacology, vol. 88, no. 5, pp. 935-948.
Teo, T, Yang, Y, Yu, M, Sunita, K, Gillam, T, Hou, J, Schmid, R, Kumarasiri, M, Diab, S, Albrecht, H, Sykes, M & Wang, S 2015, 'An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis', European Journal of Medicinal Chemistry, vol. 103, pp. 539-550.
3 4 2
Teo, THS, Lam, FK, Yu, M, YANG, Y, KC Basnet, S, Albrecht, H, Sykes, MJ & Wang, S 2015, 'Pharmacologic inhibition of MNKs in acute myeloid leukemia', Molecular Pharmacology, vol. 88, no. 2, pp. 380-389.
Yu, M, Li, P, KC Basnet, S, Kumarasiri, M, Al Haj Diab, S, Teo, THS, Albrecht, H & Wang, S 2015, 'Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d[pyrimidine derivatives as potent Mnk inhibitors: Synthesis, structure-activity relationship analysis and biological evaluation', European Journal of Medicinal Chemistry, vol. 95, pp. 116-126.
Diab, S, Teo, THS, Kumarasiri, M, Li, P, Yu, M, Lam, F, Basnet, SK, Sykes, MJ, Albrecht, H, Milne, R & Wang, S 2014, 'Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors : synthesis, SAR analysis and biological evaluation', ChemMedChem, vol. 9, no. 5, pp. 962-972.
Open access 18 20
Joesch, C, Guevarra, E, Parel, S, Bergner, A, Zbinden, P, Konrad, D & Albrecht, H 2008, 'Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and µARCS technologies: Identification of ion channel modulators acting on the GABAA receptor', Journal of Biomolecular Screening, vol. 13, no. 3, pp. 218-228.
Supervisions from 2010 shown
|Thesis title||Student status|
|Development of selective kallikrein-related peptidase 4 inhibitor: a promising therapeutic option for prostate cancer||Current|
|Identification and characterisation of Mnk inhibitors as potential anti-cancer agents||Current|
|Study of bombesin modified elastin-like polypeptides drug delivery nanoparticles for prostate cancer||Current|
|Targeting Cyclin-dependent kinases 4/6 for treatment of cancer||Current|